[Combined therapy of polyamine antimetabolite and nitrosourea in human gastric cancer]
Related Experiment Videos
Abstract:
Antitumor therapy using the polyamine antimetabolites, alpha-difluoromethylornithine (DFMO) and methylglyoxal-bis-guanylhydrazone (MGBG), combined with ACNU was studied in human gastric cancer xenotransplanted into nude mice. DFMO 1,000 mg/kg (in two divided doses) and MGBG 50 mg/kg were given i.p. for 6 successive days from the time when the xenotransplanted tumor weighed about 100 mg, and ACNU 20 mg/kg was given i.p. every other day from the same time. Antitumor efficacy was assessed by the time course of tumor weight as well as of DNA biosynthesis and polyamine levels in tumor tissue. Tumor weight was estimated using Battelle's Columbus Institute protocol and DNA biosynthesis was assayed biochemically by 3H-TdR injection at a prescribed interval after termination of therapy. Furthermore, tumoral polyamine levels were assayed by HPLC. This three-drug regimen showed a favorable antitumor effect, compared to those of the other two therapies with DFMO plus MGBG as well as ACNU only. These data suggest that this combined regimen may have a synergistic efficacy judging from the action mechanisms of these three drugs.
Insights
A novel three-drug regimen combining alpha-difluoromethylornithine (DFMO), methylglyoxal-bis-guanylhydrazone (MGBG), and ACNU demonstrated significant antitumor effects in human gastric cancer xenografts. This combination therapy shows promise for enhanced gastric cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Context:
- Gastric cancer remains a significant global health challenge with limited effective therapeutic options.
- Polyamines play a crucial role in cell proliferation and are implicated in cancer development.
- Existing treatments often face challenges with efficacy and resistance.
Purpose:
- To evaluate the combined antitumor efficacy of alpha-difluoromethylornithine (DFMO), methylglyoxal-bis-guanylhydrazone (MGBG), and ACNU in a human gastric cancer xenograft model.
- To assess the impact of this three-drug regimen on tumor growth, DNA biosynthesis, and polyamine levels.
- To explore the potential synergistic interactions between DFMO, MGBG, and ACNU in cancer therapy.
Summary:
- Human gastric cancer xenografts in nude mice were treated with a combination of DFMO, MGBG, and ACNU.
- Therapeutic efficacy was evaluated by monitoring tumor weight, DNA biosynthesis (using 3H-TdR), and tumoral polyamine levels (via HPLC).
- The three-drug regimen exhibited superior antitumor activity compared to DFMO/MGBG or ACNU monotherapy, suggesting synergistic effects.
Impact:
- The findings suggest a potential synergistic efficacy of the combined DFMO, MGBG, and ACNU regimen for gastric cancer treatment.
- This research provides a basis for further investigation into novel combination therapies for gastrointestinal malignancies.
- Understanding the mechanistic basis of this synergy could lead to improved therapeutic strategies and better patient outcomes.